You are subscribed to one of the following page update alerts:
Vaccine Code Set Update Publication Date: July 30, 2021
The individual filenames included in this distribution contain the publication date (20210730)
Release Notes: This release includes updates for all vaccine codes including Vaccine Information Statement (VIS) codes and maps.
General Note regarding this release: Codes with “Last Update” dates after May 17, 2021 and before July 30, 2021 reflect the changes and additions in this release. This is a large release and includes the following code set updates:
- Vaccine Code Set Updates Not Related to COVID-19
- New and retired codes for seasonal influenza vaccines
- Other vaccine code additions and changes
- COVID-19 Related Code Updates
- Non-U.S. COVID-19 vaccine code additions and updates
- Other COVID-19 Related Code Changes
Vaccine Code Set Updates
1. Vaccine Code Updates Not Related to COVID-19
- New 2021/2022 Seasonal Influenza Vaccines
Vaccine codes for the 2021/2022 seasonal influenza vaccines have been added as shown in Table 1 below. Also updated are the two website tables “2021/2022 Seasonal Influenza Codes and Crosswalk” and “Southern Hemisphere 2021 Seasonal Influenza Codes.” The two tables are available on the CDC website table using the following link: https://www.cdc.gov/vaccines/programs/iis/code-sets.html
Table 1: Seasonal Influenza NDCs Added for the 2021/2022 Influenza Season
Sale Proprietary Name | Sale Labeler | Sale NDC11 | Use NDC11 | Presentation | CVX Code | MVX Code |
|---|
Flulaval Quadrivalent | ID Biomedical Corporation of Quebec | 19515-0818-52 | 19515-0818-41 | SYRINGE, .5 mL | 150 | IDB |
|---|
FLUZONE QUADRIVALENT | Sanofi Pasteur Inc. | 49281-0421-10 | 49281-0421-58 | VIAL, .5 mL, SINGLE-DOSE | 150 | PMC |
|---|
FLUZONE QUADRIVALENT | Sanofi Pasteur Inc. | 49281-0421-50 | 49281-0421-88 | SYRINGE, .5 mL | 150 | PMC |
|---|
FLUARIX QUADRIVALENT | GlaxoSmithKline Biologicals SA | 58160-0887-52 | 58160-0887-41 | SYRINGE, .5 mL | 150 | SKB |
|---|
FLUZONE QUADRIVALENT | Sanofi Pasteur Inc. | 49281-0635-15 | 49281-0635-78 | VIAL, 5 mL, MULTI-DOSE | 158 | PMC |
|---|
FLUZONE QUADRIVALENT | Sanofi Pasteur Inc. | 49281-0521-25 | 49281-0521-00 | SYRINGE, .25 mL | 161 | PMC |
|---|
FLUCELVAX QUADRIVALENT | Seqirus Inc. | 70461-0321-03 | 70461-0321-04 | SYRINGE, .5 mL | 171 | SEQ |
|---|
Flublok Quadrivalent Northern Hemisphere | Sanofi Pasteur Inc. | 49281-0721-10 | 49281-0721-88 | SYRINGE, .5 mL | 185 | PMC |
|---|
FLUCELVAX QUADRIVALENT | Seqirus Inc. | 70461-0421-10 | 70461-0421-11 | VIAL, 5 mL, MULTI-DOSE | 186 | SEQ |
|---|
FLUZONE High-Dose Quadrivalent Northern Hemisphere | Sanofi Pasteur Inc. | 49281-0121-65 | 49281-0121-88 | SYRINGE, .7 mL | 197 | PMC |
|---|
FLUAD QUADRIVALENT | Seqirus, Inc. | 70461-0121-03 | 70461-0121-04 | SYRINGE, .5 mL | 205 | SEQ |
|---|
Waiting on the following information (not included in this release):
- FLUAD (trivalent) NDC codes have not been provided as of this release for the 2021/2022 season
- Flumist NDC codes have not been provided as of this release for the 2021/2022 season
- Afluria NDC codes have not been provided as of this release for the 2021/2022 season
- Retired 2020/2021 Seasonal Influenza NDCs
Table 2 below identifies the influenza vaccine NDC codes that have been retired for the 2020/2021 season.
Table 2: 2020/2021 Seasonal Influenza NDCs Retired
Sale Proprietary Name | Sale Labeler | Sale NDC11 | Use NDC11 |
|---|
FLUAD QUADRIVALENT | Seqirus, Inc. | 70461-0120-03 | 70461-0120-04 |
|---|
FLUARIX QUADRIVALENT | GlaxoSmithKline Biologicals SA | 58160-0885-52 | 58160-0885-41 |
|---|
Flublok Quadrivalent Northern Hemisphere | Sanofi Pasteur Inc. | 49281-0720-10 | 49281-0720-88 |
|---|
FLUCELVAX QUADRIVALENT | Seqirus Inc. | 70461-0420-10 | 70461-0420-11 |
|---|
FLUCELVAX QUADRIVALENT | Seqirus Inc. | 70461-0320-03 | 70461-0320-04 |
|---|
Flulaval Quadrivalent | ID Biomedical Corporation of Quebec | 19515-0816-52 | 19515-0816-41 |
|---|
FLUZONE High-Dose Quadrivalent Northern Hemisphere | Sanofi Pasteur Inc. | 49281-0120-65 | 49281-0120-88 |
|---|
FLUZONE QUADRIVALENT | Sanofi Pasteur Inc. | 49281-0420-50 | 49281-0420-88 |
|---|
FLUZONE QUADRIVALENT | Sanofi Pasteur Inc. | 49281-0420-10 | 49281-0420-58 |
|---|
FLUZONE QUADRIVALENT | Sanofi Pasteur Inc. | 49281-0520-25 | 49281-0520-00 |
|---|
FLUZONE QUADRIVALENT | Sanofi Pasteur Inc. | 49281-0633-15 | 49281-0633-78 |
|---|
- Other Vaccine Code Additions and Changes
Non-Influenza Vaccine NDCs Added: The following new Vaccine NDCs have been added for RabAvert.
Table 3: New Vaccine NDCs
Sale Proprietary Name | Sale Labeler | Sale NDC11 | Use NDC11 | Presentation | CVX Code | MVX Code |
|---|
RabAvert | Bavarian Nordic A/S | 50632-0010-01 | 50632-0013-01 | VIAL, SINGLE-DOSE, 1 mL | 176 | SKB |
|---|
MVX Code Changes: The following NDCs have had a change to their associated MVX Code (new MVX Codes shown)
Table 4: MVX Changes for Existing NDCs
Sale Proprietary Name | Sale Labeler | Sale NDC11 | Use NDC11 | MVX Code |
|---|
Vaxelis | MSP Vaccine Company | 663361-0243-10 | 663361-0243-58 | MSP |
|---|
Vaxelis | MSP Vaccine Company | 663361-0243-15 | 663361-0243-88 | MSP |
|---|
BCG VACCINE | Merck Sharp & Dohme Corp. | 00052-0603-01 | 0052-0603-02 | MSD |
|---|
MVC Code Changes: The following additional manufacturer MVX code additions and updates have been made.
- New Manufacturer MVX Code Added
MSP | MSP Vaccine Company - (partnership Merck and Sanofi Pasteur) | U.S. Based - Joint manufacturing partnership, initial vaccine Vaxelis 10/2020 |
|---|
OTC | Organon Teknika Corporation | Subsidiary of Merck. Sold by Merck 6/8/2021.
Effective June 2021 Merck is now labeler for the TICE BCG product. |
|---|
- Manufacturer Name Change for Existing MVX Code
PAX | Emergent Travel Health, Inc (Formerly PaxVax) | Emergent Biosolutions acquired PaxVax 8/2021,
U.S. Vaccines starting to label under Emergent Travel Health Ins. |
|---|
2. COVID-19 Related Code Updates
- Non-U.S. COVID-19 Vaccine Code Additions and Updates
The CDC has added and updated CVX codes, MVX and Product Tradename codes to support documentation of non-U.S. COVID-19 vaccine administration history records.
During the pandemic, multiple COVID-19 vaccines have been developed and are being administered internationally.
In this release, COVID-19 Non-U.S. CVX codes, associated MVX and Product Codes have been added or updated in the main code set data files to provide additional codes for use in documenting historic non-U.S. administration. A new table located on the CDC website, “COVID-19 Related Codes,” specifically identifies all CVX codes that might be used for non-U.S. vaccinations. This website table, “Preview Posting of COVID-19 Vaccine Codes and Crosswalks to be used for non-U.S. vaccine administration,” provides all the new/updated CVX codes in one place including associated code notes that can provide guidance for documenting COVID-19 vaccines administered outside of U.S. jurisdiction. The on-line table and downloadable files are available on this link: https://www.cdc.gov/vaccines/programs/iis/COVID-19-related-codes.html#codes
Additional Notes: The list of vaccines not authorized by the WHO may be incomplete. The list of vaccines indicated to be WHO-authorized will be updated periodically as the CDC monitors WHO-published information. All the COVID-19 related CVX codes are associated to the Vaccine Group "COVID-19."
Updates and additions to the CVX codes for COVID-19 include:
- Six existing COVID-19 CVX codes have had the Notes field updated to provide non-U.S. tradenames and use guidance, one code has changed status (see AstraZeneca below)
- Twelve new COVID-19 non-U.S. CVX codes have been added to reflect vaccines known to be available in the global market. Two of these are indicated as WHO-authorized vaccines which will be counted toward U.S. immunity. For the two WHO-authorized vaccines, new MVX codes and Product table codes have been added and associated to those CVX codes.
Two MVX codes have been added for the WHO authorized COVID-19 non-US vaccines:
MVX Code | Manufacturer | Notes | Status |
|---|
SPH | Sinopharm-Biotech | Non-US COVID-19 Vaccine Manufacturer - WHO Authorized | Active |
|---|
SNV | Sinovac | Non-US COVID-19 Vaccine Manufacturer - WHO Authorized (Sinovac, CoronaVac) | Active |
|---|
Five CDC Product Tradename table records have been updated or added to incorporate international tradenames that may appear on non-US vaccine record for U.S. and WHO authorized vaccines:
Product Tradename(s) | CVX Code | MVX Code |
|---|
AstraZeneca COVID-19 Vaccine (Non-US tradenames include VAXZEVRIA, COVISHIELD) | 210 | ASZ |
|---|
Coronavac (Sinovac) COVID-19 Vaccine | 511 | SNV |
|---|
Moderna COVID-19 Vaccine (non-US Spikevax) | 207 | MOD |
|---|
Sinopharm (BIBP) COVID-19 Vaccine | 510 | SPH |
|---|
Pfizer-BioNTech COVID-19 Vaccine (Non-US COMIRNATY) | 208 | PFR |
|---|
- Other COVID-19 Related Code Changes
AstraZeneca COVID-19 vaccine NDC codes have been temporarily inactivated pending U.S. regulatory submission and FDA review. The end dates for Unit of Sale NDC11 00310-1222-15 and Unit of Use NDC11 00310-1222-10 have been set to 7/31/2021. The following changes have also been made.
- CVX Code 210 for AstraZeneca COVID-19 vaccine; status has been changed to “non-US” from “active” to reflect that this vaccine is currently only available outside the U.S.
- The VIS Edition Status for the EUA Recipient Fact Sheet has been changed to “Historic” from “Current”
